Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the provided label excerpts for dosing interval and the presence of pneumonia/skin/intra-abdominal indications via duration. Several claims (broad-spectrum, glycylcycline term, mechanism, resistance/severity wording, and renal adjustment) are unsupported or not verifiable from the supplied label text. A full safety audit cannot be completed because contraindications/boxed warnings/drug interactions and other safety sections were not provided.
Category Scores
Accurate Statements
Tigecycline is administered intravenously every 12 hours.
2.1 Recommended Adult Dosage: “Intravenous infusions … administered … every 12 hours” and “50 mg every 12 hours.”
Unsupported Statements
Tigecycline is a broad-spectrum antibiotic.
The provided label excerpts do not explicitly state “broad-spectrum.” Tigecycline is described as a “tetracycline class antibacterial,” but broad-spectrum wording is not present in the supplied text.
Tigecycline is used to treat severe infections, including those caused by resistant bacteria.
The provided label excerpts do not include 1 INDICATIONS AND USAGE wording. In the provided 2.1 excerpt, dosing durations are shown for specific listed indications, but the provided text does not include language about severity/resistant bacteria.
Tigecycline is a glycylcycline antibiotic.
The provided label excerpts do not use the term “glycylcycline.” They describe tigecycline as a tetracycline class antibacterial.
Tigecycline works by inhibiting protein synthesis in bacteria.
The provided label excerpts do not state “inhibiting protein synthesis.” 12.1 only states it is a “tetracycline class antibacterial” and links to Microbiology (12.4), which is not included in the supplied text.
The recommended dose of tigecycline is 100 mg.
2.1 states an initial dose of 100 mg followed by 50 mg every 12 hours; the claim omits that it is the initial dose only.
The dosing regimen of tigecycline may need to be adjusted based on the patient's renal function and other factors.
The provided excerpts do not mention renal-function-based dose adjustment. Renal adjustment guidance could be in another subsection not included here.
Contradictions
Important Omissions
Recommended regimen detail: initial 100 mg followed by 50 mg every 12 hours (maintenance dosing).
Importance:
Moderate
Administration infusion duration: administer over approximately 30 to 60 minutes every 12 hours.
Importance:
Moderate
Treatment duration ranges by indication (e.g., 5–14 days for complicated skin/skin structure and complicated intra-abdominal infections; 7–14 days for community-acquired bacterial pneumonia) and guidance by severity/site/clinical and bacteriological progress.
Importance:
Moderate
Safety labeling content (contraindications, boxed warning/Warnings and precautions, drug interactions, and specific populations) was not addressed in the extracted claims, and corresponding label sections were not provided for verification.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported or not verifiable from the provided label excerpts, including a potentially safety-relevant dosing concept (renal function adjustment) that is not shown in the supplied text, and key regimen details (maintenance dose, infusion duration, and treatment duration) are omitted or imprecisely stated. Full safety audit is limited due to missing label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple mechanistic/descriptor and safety-relevant dosing-adjustment claims are unsupported or not verifiable from the supplied label excerpts; regimen details (initial vs maintenance, infusion duration, treatment duration) are incomplete/omitted.
Suggested Improvement
Restrict statements to what is explicitly supported by the provided label text (e.g., initial 100 mg followed by 50 mg every 12 hours; infusion over ~30–60 minutes; indication support via provided dosing-duration section). Omit or qualify claims about broad-spectrum wording, glycylcycline term, resistance/severity wording, mechanism, and renal adjustment unless the corresponding label sections are provided and explicitly state those points.